As filed with the Securities and Exchange Commission
on August 14, 2023
Registration
Statement No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
Jaguar Health, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
(State or other jurisdiction of incorporation or
organization) |
46-2956775
(I.R.S. Employer Identification No.) |
200
Pine Street, Suite 400
San Francisco, California 94104
(Address of principal executive office) (Zip Code)
2014 Stock Incentive Plan
as amended and restated May 14, 2023
(Full title of the plan)
Lisa
A. Conte
Chief Executive Officer and President
Jaguar Health, Inc.
200 Pine Street, Suite 400
San Francisco, California 94104
(415) 371-8300
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
| Donald C. Reinke |
|
Jeffrey G. Aromatorio |
| Reed Smith LLP |
|
Reed Smith LLP |
| 101 Second Street, Suite 1800 |
|
Reed Smith Centre, 225 Fifth Avenue |
| San Francisco, California 94105 |
|
Pittsburgh, PA 15222 |
| (415) 543-8700 |
|
(412) 288-3364 |
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated
filer ¨
Non-accelerated
filer x |
Accelerated
filer ¨
Smaller reporting
company x
Emerging growth
company ¨ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨ |
EXPLANATORY NOTE
This Registration Statement
on Form S-8 is filed by Jaguar Health, Inc. (f/k/a Jaguar Animal Health, Inc.), a Delaware corporation (the “Registrant”),
relating to 2,700,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible employees,
consultants, and non-employee directors of the Registrant under the Registrant’s 2014 Stock Incentive Plan (the “Plan”),
as amended and restated through May 14, 2023, which Common Stock is in addition to (a) the 1 share of Common Stock registered on the Registrant’s
Form S-8 filed on May 18, 2015 (File No. 333-204280), (b) the 7 shares of Common Stock registered on the Registrant’s Form S-8 filed on December 23, 2016 (File No. 333-215303), (c) the 28 shares of Common Stock registered on the Registrant’s Form S-8 filed on August 14, 2017 (File No. 333-219939), (d) the 3 shares of Common Stock registered on the Registrant’s Form S-8 filed on May 18, 2018 (File No. 333-225057), (e) the 20,777 shares of Common Stock registered on the Registrant’s Form S-8 filed on April 24, 2020 (File No. 333-237816), (f) the 25,338 shares of Common Stock registered on the Registrant’s Form S-8 filed on May 28, 2021 (File No. 333-256626), (g) the 32,235 shares of Common Stock registered on the Registrant’s Form S-8 filed on April 13, 2022 (File No. 333-264276), and (h) the 109,104 shares of Common Stock registered on the Registrant’s Form S-8 filed on April 6, 2023 (File No. 333-271156) (collectively, the “Prior Registration Statements”). All of the share amounts presented herein reflect the
15-to-1 reverse stock split effective June 1, 2018, the 70-to-1 reverse stock split effective June 7, 2019, the 3-to-1 reverse stock split
effective September 8, 2021, and the 75-to-1 reverse stock split effective January 23, 2023.
This Registration Statement
relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with
General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the
contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except
as amended hereby.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The document(s) containing the information specified in Part I of Form
S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Certain Documents by Reference
The following documents of Registrant filed with
the Securities and Exchange Commission (File No. 001-36714) are incorporated herein by reference:
| (c) | Registrant’s Current Reports on Form 8-K filed on January 6, 2023, January 23, 2023 (except
Item 7.01), February 6, 2023 (except Item 7.01), February 8, 2023, May 9, 2023 (except Item 7.01), May 12, 2023, May 19, 2023 (except
Item 7.01), July 3, 2023, and July 7, 2023 (except Item 7.01); and |
| (d) | The description of our common stock filed as Exhibit 4.26 to Registrant’s Annual Report on Form
10-K for the fiscal year ended December 31, 2019 filed on April 3, 2020, including any amendment or report filed for the purpose of updating
such description. |
All documents subsequently
filed by Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment
which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be
deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents;
provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall
not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion
of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of
this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is
or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 8. Exhibits.
See Exhibit Index immediately following the Signature
Pages.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco,
State of California, on this 14th day of August, 2023.
| |
JAGUAR HEALTH,
INC. |
| |
|
|
| |
By: |
/s/
Lisa A. Conte |
| |
|
Name: |
Lisa A. Conte |
| |
|
Title: |
Chief Executive Officer and President |
POWER OF ATTORNEY
KNOW ALL
PERSONS BY THESE PRESENTS, that each person whose signature appears below constitute and appoint Lisa A. Conte and Carol Lizak,
and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution,
for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority
to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them,
or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | |
Title | |
Date |
/s/ Lisa A. Conte | |
Chief Executive Officer, President, and Director | |
August 14, 2023 |
| Lisa A. Conte | |
(Principal Executive Officer) | |
|
| | |
| |
|
| /s/ Carol Lizak | |
Chief Financial Officer and Treasurer (Principal | |
August 14, 2023 |
| Carol Lizak | |
Financial and Accounting Officer) | |
|
| | |
| |
|
| /s/ James J. Bochnowski | |
Chairman of the Board of Directors | |
August 14, 2023 |
| James J. Bochnowski | |
| |
|
| | |
| |
|
| /s/ Dr. Anula Jayasuriya | |
Director | |
August 14, 2023 |
| Dr. Anula Jayasuriya | |
| |
|
| | |
| |
|
| /s/ John Micek III | |
Director | |
August 14, 2023 |
| John Micek III | |
| |
|
| | |
| |
|
| /s/ Jonathan B. Siegel | |
Director | |
August 14, 2023 |
| Jonathan B. Siegel | |
| |
|
EXHIBIT INDEX
Exhibit 5.1
August 14, 2023
Jaguar Health, Inc.
200 Pine Street, Suite 400
San Francisco, California 94104
Ladies and Gentlemen:
We have acted as counsel to Jaguar Health, Inc., a Delaware corporation
(the “Company”), in connection with the filing by the Company on the date hereof of a Registration Statement on Form
S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) covering
the offer and sale of up to 2,700,000 shares of the Company’s common stock, $0.0001 par value per share (the “Shares”),
issuable pursuant to its 2014 Stock Incentive Plan (the “Plan”), as amended and restated through May 14, 2023. This
opinion is being furnished at the Company’s request in connection with the requirements of Item 601(b)(5) of Regulation S-K under
the Securities Act of 1933, as amended, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration
Statement or the prospectus forming a part thereof, other than as to the issue of the Shares.
In rendering the opinion hereinafter expressed, we have made such legal
and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified to our satisfaction
as being true reproductions of originals, of all such documents, records, agreements and other instruments, including the Registration
Statement, the Plan, the Certificate of Incorporation, as amended, of the Company, the Bylaws of the Company, and corporate minutes of
the Company as we have deemed necessary and appropriate for the purpose of this opinion. We have assumed that there are no agreements
or understandings between or among the Company and any participants in the Plan that would expand, modify or otherwise affect the terms
of the Plan or the respective rights or obligations of any participants thereunder. We have further assumed the genuineness of all signatures,
the authenticity of all documents, certificates and records submitted to us as originals, the conformity to original documents, certificates
and records of all documents, certificates and records submitted to us as copies, and the truthfulness of all statements of fact contained
therein.
Based upon the foregoing, and having regard to legal considerations
and other information that we deem relevant, we are of the opinion that, as of the date hereof, when the Shares shall have been duly registered
on the books of the transfer agent and registrar therefor in the name or on behalf of the participants, and have been issued by the Company
against payment therefor in the circumstances contemplated by the Plan and assuming in each case that the individual issuances, grants
or awards under the Plan are duly authorized by all necessary corporate action of the Company and duly issued, granted or awarded and
exercised and paid for, for consideration at least equal to the par value thereof, in accordance with the requirements of law and the
Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares shall have
been duly authorized by all necessary corporate action of the Company and, when and to the extent that the Shares are issued in accordance
with the foregoing, such Shares will be validly issued, fully paid and non-assessable.
We express no opinion herein as to the laws of any state or jurisdiction
other than the General Corporation Law of the State of Delaware.
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and the reference to this firm therein. In giving this consent, we do not thereby admit that we are within the
category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours,
/s/ Reed Smith LLP
Reed Smith LLP
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
Jaguar Health, Inc.
San Francisco, California
We consent to the incorporation by reference in this Registration Statement
on Form S-8 dated August 14, 2023, of our report dated March 24, 2023, relating to the consolidated financial statements of Jaguar Health,
Inc. as of and for the year ended December 31, 2022 (which report includes an explanatory paragraph regarding the Company’s ability
to continue as a going concern).
/s/ RBSM, LLP
RBSM, LLP
RBSM, LLP
101 Larkspur Landing Suite 321
Larkspur, CA 94939
August 14, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Jaguar Health, Inc.
(Exact Name of Registrant as Specified in its
Charter)
Table 1: Newly Registered Securities
Security
Type |
|
Security
Class
Title |
|
Fee
Calculation
Rule |
|
Amount
Registered(1) |
|
|
Proposed
Maximum
Offering Price
Per Share |
|
|
Maximum
Aggregate
Offering Price |
|
|
Fee
Rate |
|
|
Amount
of
Registration
Fee |
|
| Equity |
|
Common
Stock, $0.0001 par value per share |
|
Rule
457(c) and Rule 457(h) |
|
|
2,700,000 |
|
|
$ |
.572 |
(2) |
|
$ |
1,544,400 |
|
|
$ |
0.0001102 |
|
|
$ |
170.19 |
|
| Total
Offering Amounts |
|
|
|
|
|
|
|
|
|
$ |
1,544,400 |
|
|
|
|
|
|
$ |
170.19 |
|
| Total Fee Offsets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
| Net Fee Due |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
170.19 |
|
| (1) |
Pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also
includes an indeterminate number of additional shares that may become issuable under the plan set forth herein by reason of any stock
split, stock dividend, recapitalization or other similar transactions as provided in the above-referenced plan. |
| |
|
| (2) |
Estimated
in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee on the
basis of $.572 per share, which is the average of the high and low prices of the Registrant’s common stock, as reported on
the NASDAQ Capital Market, on August 10, 2023. |
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Apr 2023 to Apr 2024
